Abstract
Introduction Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal-dominant neurodegenerative disease caused by mutations in the proteinase inhibitor 12 gene (PI12; SERPINI1), located on chromosome 3q26 [1]. The PI12 gene encodes the protein neuroserpin, a protein of 54–60 kDa that is expressed predominantly by neurons of the central and peripheral nervous system. Neuroserpin is a serine protease inhibitor that inhibits tissue-type plasminogen activator. Mutations in the PI12 gene lead to the formation of neuroserpin intracytoplasmic inclusion bodies (IBs), called Collins bodies, within neurons [1–3]. Accumulation of polymers composed of the mutant neuroserpin protein in IBs seems to lead to a gain of a toxic function by the mutant neuroserpin; however, loss of the normal function of neuroserpin may also contribute to the pathology, with these two mechanisms acting together to lead to the progression of the disease and neurodegeneration. In patients with FENIB, neuroserpin IBs may be found in the brain and the spinal cord. They may be also found outside the central nervous system in neurons of the dorsal root ganglion but not in cells of other organ systems [1–6]. Clinical phenotypes The onset of clinical signs and symptoms of FENIB may be highly variable depending on the specific mutation [1–8]. Patients carrying a mutation that causes high instability of neuroserpin have an earlier onset of the disease, more severe clinical manifestations, a shorter life expectancy and numerous IBs when compared with patients with a more stable mutant form of neuroserpin. The disease, which occurs equally in males and females, may present with progressive myoclonus epilepsy, focal or generalized seizures, dysarthria, tremors and dementia. Affected individuals consistently demonstrate deficits in areas associated with frontal-lobe processes. The course of the disease can be quite long, exceeding 10 years in some cases. Prior to the onset of neurological signs, mutation carriers have almost intact cognition, with the exception of restricted attention, concentration and oral fluency [8].
| Original language | English (US) |
|---|---|
| Title of host publication | Neuropathology of Neurodegenerative Diseases: A Practical Guide |
| Publisher | Cambridge University Press |
| Pages | 259-262 |
| Number of pages | 4 |
| ISBN (Print) | 9781107588660, 9781107674202 |
| DOIs | |
| State | Published - Jan 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Other neurodegenerative conditions II. / Vidal, Ruben; Ghetti, Bernardino.
Neuropathology of Neurodegenerative Diseases: A Practical Guide. Cambridge University Press, 2014. p. 259-262.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Other neurodegenerative conditions II
AU - Vidal, Ruben
AU - Ghetti, Bernardino
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Introduction Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal-dominant neurodegenerative disease caused by mutations in the proteinase inhibitor 12 gene (PI12; SERPINI1), located on chromosome 3q26 [1]. The PI12 gene encodes the protein neuroserpin, a protein of 54–60 kDa that is expressed predominantly by neurons of the central and peripheral nervous system. Neuroserpin is a serine protease inhibitor that inhibits tissue-type plasminogen activator. Mutations in the PI12 gene lead to the formation of neuroserpin intracytoplasmic inclusion bodies (IBs), called Collins bodies, within neurons [1–3]. Accumulation of polymers composed of the mutant neuroserpin protein in IBs seems to lead to a gain of a toxic function by the mutant neuroserpin; however, loss of the normal function of neuroserpin may also contribute to the pathology, with these two mechanisms acting together to lead to the progression of the disease and neurodegeneration. In patients with FENIB, neuroserpin IBs may be found in the brain and the spinal cord. They may be also found outside the central nervous system in neurons of the dorsal root ganglion but not in cells of other organ systems [1–6]. Clinical phenotypes The onset of clinical signs and symptoms of FENIB may be highly variable depending on the specific mutation [1–8]. Patients carrying a mutation that causes high instability of neuroserpin have an earlier onset of the disease, more severe clinical manifestations, a shorter life expectancy and numerous IBs when compared with patients with a more stable mutant form of neuroserpin. The disease, which occurs equally in males and females, may present with progressive myoclonus epilepsy, focal or generalized seizures, dysarthria, tremors and dementia. Affected individuals consistently demonstrate deficits in areas associated with frontal-lobe processes. The course of the disease can be quite long, exceeding 10 years in some cases. Prior to the onset of neurological signs, mutation carriers have almost intact cognition, with the exception of restricted attention, concentration and oral fluency [8].
AB - Introduction Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal-dominant neurodegenerative disease caused by mutations in the proteinase inhibitor 12 gene (PI12; SERPINI1), located on chromosome 3q26 [1]. The PI12 gene encodes the protein neuroserpin, a protein of 54–60 kDa that is expressed predominantly by neurons of the central and peripheral nervous system. Neuroserpin is a serine protease inhibitor that inhibits tissue-type plasminogen activator. Mutations in the PI12 gene lead to the formation of neuroserpin intracytoplasmic inclusion bodies (IBs), called Collins bodies, within neurons [1–3]. Accumulation of polymers composed of the mutant neuroserpin protein in IBs seems to lead to a gain of a toxic function by the mutant neuroserpin; however, loss of the normal function of neuroserpin may also contribute to the pathology, with these two mechanisms acting together to lead to the progression of the disease and neurodegeneration. In patients with FENIB, neuroserpin IBs may be found in the brain and the spinal cord. They may be also found outside the central nervous system in neurons of the dorsal root ganglion but not in cells of other organ systems [1–6]. Clinical phenotypes The onset of clinical signs and symptoms of FENIB may be highly variable depending on the specific mutation [1–8]. Patients carrying a mutation that causes high instability of neuroserpin have an earlier onset of the disease, more severe clinical manifestations, a shorter life expectancy and numerous IBs when compared with patients with a more stable mutant form of neuroserpin. The disease, which occurs equally in males and females, may present with progressive myoclonus epilepsy, focal or generalized seizures, dysarthria, tremors and dementia. Affected individuals consistently demonstrate deficits in areas associated with frontal-lobe processes. The course of the disease can be quite long, exceeding 10 years in some cases. Prior to the onset of neurological signs, mutation carriers have almost intact cognition, with the exception of restricted attention, concentration and oral fluency [8].
UR - http://www.scopus.com/inward/record.url?scp=84955066868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955066868&partnerID=8YFLogxK
U2 - 10.1017/CBO9781107588660.014
DO - 10.1017/CBO9781107588660.014
M3 - Chapter
AN - SCOPUS:84955066868
SN - 9781107588660
SN - 9781107674202
SP - 259
EP - 262
BT - Neuropathology of Neurodegenerative Diseases: A Practical Guide
PB - Cambridge University Press
ER -